IP Verse

Cross Reactive Siglec Antibodies - EP3191517

The patent EP3191517 was granted to Innate Pharma on Nov 4, 2020. The application was originally filed on Sep 9, 2015 under application number EP15762562A. The patent is currently recorded with a legal status of "Revoked".

EP3191517

INNATE PHARMA
Application Number
EP15762562A
Filing Date
Sep 9, 2015
Status
Revoked
Jun 16, 2023
Grant Date
Nov 4, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GRAF VON STOSCHAug 3, 2021-ADMISSIBLE

Patent Citations (1) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONWO2016038064

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Jason E Hudak ET AL, "Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion-Supplementary information", NATURE CHEMICAL BIOLOGY, Basingstoke, (20131124), vol. 10, no. 1, doi:10.1038/nchembio.1388, ISSN 1552-4450, pages S1 - S21, XP055372305
EXAMINATION- Camilla Jandus ET AL, "Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance", JOURNAL OF CLINICAL INVESTIGATION, GB, (20140224), vol. 124, no. 4, doi:10.1172/JCI65899, ISSN 0021-9738, pages 1810 - 1820, XP055342636
OPPOSITION- KUMAR et al., "A NEW SELF: MHC-CLASS-IINDEPENDENT NATURAL-KILLERCELL SELF-TOLERANCE", Nat Rev Immunol, (20050000), vol. 5, no. 5, pages 363 - 74, XP055920839-
OPPOSITION- Lnbal Sela-Culang, Vered Kunikt Andyanay Ofran, "The structural basis of antibody-antigen recognition", Front Immunol, (20131001), vol. 4, XP055920843-
OPPOSITION- Paul R. Crocker, James C. Paulson, Ajit Varki, "Siglecs and their roles in the immune system", Nature Reviews Immunology, Nature Pub. Group, (20070401), vol. 7, no. 4, doi:10.1038/nri2056, ISSN 14741733, pages 255 - 266, XP055078140
OPPOSITION- NICOLL G, ET AL., "IDENTIFICATION AND CHARACTERIZATION OF A NOVEL SIGLEC, SIGLEC-7, EXPRESSED BY HUMAN NATURAL KILLER CELLS AND MONOCYTES", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19991126), vol. 274, no. 48, doi:10.1074/jbc.274.48.34089, ISSN 0021-9258, pages 34089 - 34095, XP002926724
OPPOSITION- ZHANG J Q, ET AL., "SIGLEC-9, A NOVEL SIALIC ACID BINDING MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY EXPRESSED BROADLY ON HUMAN BLOOD LEUKOCYTES", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20000721), vol. 275, no. 29, doi:10.1074/jbc.M002788200, ISSN 0021-9258, pages 22121 - 22126, XP002909451
OPPOSITION- Nivedita Mitra, Kalyan Banda, Tasha K. Altheide, Lana Schaffer, Teresa L. Johnson-Pais, Joke Beuten, Robin J. Leach, Takashi Angata, Nissi Varki, Ajit Varki, "SIGLEC12 , a Human-specific Segregating (Pseudo)gene, Encodes a Signaling Molecule Expressed in Prostate Carcinomas", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20110701), vol. 286, no. 26, doi:10.1074/jbc.M111.244152, ISSN 0021-9258, pages 23003 - 23011, XP055649884
OPPOSITION- Camilla Jandus, Kayluz Frias Boligan, Obinna Chijioke, He Liu, Meike Dahlhaus, Thomas Démoulins, Christoph Schneider, Marc Wehrli, Robert E. Hunger, Gabriela M. Baerlocher, Hans-Uwe Simon, Pedro Romero, Christian Münz, Stephan Von Gunten, "Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance", The Journal of Clinical Investigation, B M J Group, GB, GB , (20140401), vol. 124, no. 4, doi:10.1172/JCI65899, ISSN 0021-9738, pages 1810 - 1820, XP055342636
OPPOSITION- Romagne Francois; Andre Pascale; Spee Pieter; Zahn Stefan; Anfossi Nicolas; Gauthier Laurent; Capanni Marusca; Ruggeri Loredana; Benson Don M Jr; Blaser Bradley W; Della Chiesa Mariella; Moretta Alessandro; Vivier Eric; Caligiuri Michael A; Velardi Andrea; Wagtmann Nicolai, "Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells", Blood, American Society of Hematology, US, US , (20090924), vol. 114, no. 13, doi:10.1182/blood-2009-02-206532, ISSN 0006-4971, pages 2667 - 2677, XP008120342
OPPOSITION- H. E. Kohrt, R. Houot, M. J. Goldstein, K. Weiskopf, A. A. Alizadeh, J. Brody, A. Muller, R. Pachynski, D. Czerwinski, S. Coutre, M. P. Chao, L. Chen, T. F. Tedder, R. Levy, "CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies", Blood, (20110224), vol. 117, no. 8, doi:10.1182/blood-2010-08-301945, ISSN 00064971, pages 2423 - 2432, XP055034541

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents